LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £116.50 -226.00 (-1.90%) As of 09/9/2026 12:36 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesNews and Trends About AstraZeneca Stock (LON:AZN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AstraZeneca alerts:Sign Up Key Stats Today's Range£115.98▼£119.9850-Day Range£114.60▼£145.3852-Week Range£107.84▼£157.32Volume3.34 million shsAverage Volume30.11 million shsMarket Capitalization£180.68 billionP/E Ratio17.44Dividend Yield1.99%Price Target£151.14Consensus RatingModerate Buy Company Overview AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. Read More AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 88% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAstraZeneca has a consensus price target of £151.14, representing about 29.7% upside from its current price of £116.50.Amount of Analyst CoverageAstraZeneca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 17.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.39.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 17.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 211.61.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.99%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 47.41%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. News and Social Media2.6 / 5News Sentiment0.23 News SentimentAstraZeneca has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for AstraZeneca this week, compared to 4 articles on an average week.Search Interest28 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by Insiders0.15% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions67.75% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZN Stock News HeadlinesCould AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?September 9 at 6:25 PM | finance.yahoo.comAmgen, AstraZeneca combination improves survival measures in late-stage lung cancer studySeptember 9 at 8:23 AM | msn.comSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices. | Freedom Financial (Ad)AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 TrialsSeptember 8 at 12:19 PM | finance.yahoo.comAstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPDSeptember 8 at 12:19 PM | rttnews.comAmgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC StudySeptember 8 at 12:19 PM | rttnews.comAstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast CancerSeptember 8 at 7:18 AM | rttnews.comAstraZeneca Announces Approval Of Etcamah Combination In The USSeptember 7 at 6:16 AM | rttnews.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £137.90 on January 1st, 2026. Since then, AZN shares have decreased by 15.5% and is now trading at £116.50. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees96,100Year FoundedN/APrice Target and Rating Average Price Target for AstraZeneca£151.14 High Price Target£178 Low Price Target£115 Potential Upside/Downside+29.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)GBX 668 Trailing P/E Ratio17.44 Forward P/E Ratio15.97 P/E Growth0.86Net Income£8.71 billion Net Margins17.02% Pretax MarginN/A Return on Equity21.68% Return on Assets7.68% Debt Debt-to-Equity Ratio64.10 Current Ratio0.89 Quick Ratio0.59 Sales & Book Value Annual Sales£61.37 billion Price / Sales2.94 Cash FlowGBX 299.56 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book4.43Miscellaneous Outstanding Shares1,550,896,000Free FloatN/AMarket Cap£180.68 billion OptionableNot Optionable Beta0.21 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:AZN) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredACTION TAKERS WANTED : Big Elon OpportunityJames Altucher says an FCC filing points to Elon Musk's next major venture, one he believes could dwarf Tesla ...Paradigm Press | SponsoredThe buyers of US debt are vanishing [where the money's going]$9 trillion in US government debt must be rolled over in the next 12 months. Foreign central banks in China, J...Golden Portfolio | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
